COVID-19: Implications for Patients With CLL

Keep abreast of ongoing developments in providing optimal care for patients with CLL during COVID-19 and evolving research into countering COVID-19–associated inflammatory cytokine production! Get expert perspectives on emerging data with focused commentaries, an FAQ module, and a “living” slideset regularly updated to incorporate the most important clinical findings on CLL and COVID-19.
John Pagel Headshot
John Pagel, MD, PhD
Jeff P. Sharman, MD
person default
Jacob D. Soumerai, MD

ClinicalThought

What conclusions can we draw from these preliminary data for the use of BTK inhibitors to treat the hyperinflammatory immune response in patients with severe COVID-19?

Jeff P. Sharman, MD Released: June 16, 2020

How are you using telemedicine or other strategies to manage your patients with CLL during the COVID-19 pandemic?

John Pagel Headshot John Pagel, MD, PhD Released: July 13, 2020

With the first 6 months of the COVID-19 pandemic behind us, I share how my management of patients with CLL has evolved based on experience and key data emerging on COVID-19 risk in patients with CLL.

person default Jacob D. Soumerai, MD Released: September 30, 2020

Downloadable Slideset

Download this living slideset from the live Webinar on the management of patients with CLL during the COVID-19 pandemic and check back often for updates as the situation evolves and more data are available.

Released: July 2, 2020
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue